LifeStance Health Group, Inc. (NASDAQ:LFST) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Monica Prokocki - Vice President, Investor Relations Ken Burdick - Chief Executive Officer Dave Bourdon - Chief Financial Officer Danish Qureshi - Chief Operating Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JP Morgan Jack Senft - William Blair Kevin Caliendo - UBS Jamie Perse - Goldman Sach Brian Tanquilut - Jefferies Gary Taylor - TD Cowen Oper ...

Use of Non-GAAP Financial Measures Market and Industry Data Forward-Looking Statements In addition to financial measures presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation includes certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, Adjusted EBITDA Margin and Free Cash Flow. These non-GAAP measures are in addition to, and not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40478 LifeStance Health Group, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 86-1832801 | | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR | Delaware | 86-1832801 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 4800 N. Scottsdale Road Suite 6000 | | | Scottsdale, Arizona | 85251 | | (Address of principal executive offices) | (Zip Code) | ...

| --- | --- | --- | |--------------------------------|-------|-------------------------------| | | | | | | | | | $68M Cash & Cash Equivalents | | $225M Net Long-term Debt* | | ($8M) Operating Cash Flow (Q1) | | $8M Capital Expenditures (Q1) | De Novos Selective deployment to enable clinician and market growth Opened 3 de novos in Q1 Acquisitions 4 • Q1 Revenue of $252.6 million increased 24% year-over-year • Total clinicians of 5,961, +19% Y/Y; 330 net clinician adds in Q1 • Q1 Center Margin of $69.6 millio ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Monica Prokocki - Investor Relations Ken Burdick - Chief Executive Officer Dave Bourdon - Chief Financial Officer Danish Qureshi - Chief Operating Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JPMorgan Kevin Caliendo - UBS Jamie Perse - Goldman Sachs Brian Tanquilut - Jefferies Operator Good day, and welcome to the LifeStance Health First Quarter 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40478 LifeStance Health Group, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 86-1832801 | | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40478 LifeStance Health Group, Inc. (Exact name of Registrant as specified in its Charter) Delaware 86-1832801 (State or other jurisd ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Monica Prokocki - Vice President, Investor Relations Ken Burdick - Chief Executive Officer Dave Bourdon - Chief Financial Officer Danish Qureshi - Chief Operating Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JPMorgan Jack Senft - William Blair Brian Tanquilut - Jefferies Jamie Perse - Goldman Sachs Kevin Caliendo - UBS Operator Ladies and gentlemen, ...

Financial Data and Key Metrics Changes - Revenue for Q3 2022 was $218 million, representing a 25% year-over-year increase, driven by a 24% growth in clinician numbers [25][9] - Center margin increased to $60 million, up 16% year-over-year, although sequential expansion was not achieved due to lower-than-expected revenue and higher employee health benefit costs [25][9] - Adjusted EBITDA grew 44% year-over-year to $15 million, or 7.1% of revenue, impacted by higher health benefits costs [26][9] - The company lowered its full-year revenue guidance to $845 million to $850 million, with adjusted EBITDA expectations of $50 million to $53 million [11][9] Business Line Data and Key Metrics Changes - The clinician base grew to 5,431, with 205 net additions in Q3, primarily from organic growth [32][9] - The company completed three acquisitions in the quarter, but is moderating M&A activities to focus on organic growth [35][9] Market Data and Key Metrics Changes - The percentage of telehealth visits remains high in the 70s, although there is a gradual shift towards in-person visits [54][9] - The company is experiencing no shortage of patient demand, indicating a strong market for mental health services [68][9] Company Strategy and Development Direction - The company aims to evolve from a growth-focused mindset to a balanced approach that includes operational excellence and profitability [22][9] - Future priorities include enhancing clinician productivity, simplifying administrative processes, and focusing on larger acquisition targets [21][9][65] - The company plans to invest in scalable infrastructure and digital solutions to improve operational efficiency [19][9][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledges underperformance relative to potential and emphasizes a focus on execution and operational excellence [12][31] - The leadership team is committed to building a robust infrastructure to support long-term growth and profitability [23][9] - The company anticipates a year of transition in 2023, with slower growth but strategic investments in infrastructure [23][9] Other Important Information - The company is establishing a business transformation office to optimize processes and enhance operational efficiency [48][9] - New leadership appointments include a Business Transformation Officer and a new CFO, indicating a strategic shift in management focus [49][9] Q&A Session Summary Question: What are the revised long-term growth expectations? - Management indicated that growth will moderate to build infrastructure and capitalize on future opportunities [52][9] Question: What is the current percentage of virtual visits? - The percentage of telehealth visits is currently in the high 70s, with plans to adjust physical real estate usage accordingly [54][9] Question: Why is the company becoming more selective with payers? - The complexity of managing over 400 payer contracts and variability in reimbursement rates are key reasons for this strategic shift [56][9][58] Question: How does the company plan to address clinician capacity and utilization? - The primary issue is reduced clinician capacity due to elevated time off, while patient demand remains strong [68][9] Question: What are the expectations for accounts receivable in the fourth quarter? - Specific payer-related issues are expected to resolve in the fourth quarter, improving cash collection efficiency [70][9]